Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it ...

A biopharmaceutical company and its executives misled investors ahead of its 2024 initial public offering about a key ...

GLP-1 RA drugs help treat diabetes by weight loss, improving blood glucose levels and increasing insulin sensitivity, low ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new ...